cardiovascular

Bayer has put the blood-thinning drug through its paces in the Phase 3 trial to determine if it could help patients at risk from heart attacks and strokes due to a type of artery disease. The trial was scheduled to end by 2018, however it has proven to be so successful that Bayer could end